JP2016503752A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016503752A5 JP2016503752A5 JP2015527377A JP2015527377A JP2016503752A5 JP 2016503752 A5 JP2016503752 A5 JP 2016503752A5 JP 2015527377 A JP2015527377 A JP 2015527377A JP 2015527377 A JP2015527377 A JP 2015527377A JP 2016503752 A5 JP2016503752 A5 JP 2016503752A5
- Authority
- JP
- Japan
- Prior art keywords
- salt
- pharmaceutical composition
- crystals
- added
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 16
- 239000013078 crystal Substances 0.000 claims description 12
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- QGCKNIAMHUUUDI-LBPRGKRZSA-N (2s)-7-tert-butyl-6-chloro-2-(trifluoromethyl)-2h-chromene-3-carboxylic acid Chemical compound O1[C@H](C(F)(F)F)C(C(O)=O)=CC2=C1C=C(C(C)(C)C)C(Cl)=C2 QGCKNIAMHUUUDI-LBPRGKRZSA-N 0.000 claims 1
- 206010006811 Bursitis Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000034656 Contusions Diseases 0.000 claims 1
- 102000010907 Cyclooxygenase 2 Human genes 0.000 claims 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 claims 1
- 208000005171 Dysmenorrhea Diseases 0.000 claims 1
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000005107 Premature Birth Diseases 0.000 claims 1
- 206010036590 Premature baby Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 201000002661 Spondylitis Diseases 0.000 claims 1
- 208000010040 Sprains and Strains Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000009519 contusion Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 238000005469 granulation Methods 0.000 claims 1
- 230000003179 granulation Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- -1 meglumine salt Salt Chemical class 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 150000004682 monohydrates Chemical group 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 238000007873 sieving Methods 0.000 claims 1
- 239000007909 solid dosage form Substances 0.000 claims 1
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 36
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 239000002002 slurry Substances 0.000 description 7
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261746945P | 2012-12-28 | 2012-12-28 | |
| US61/746,945 | 2012-12-28 | ||
| PCT/JP2014/000010 WO2014104414A1 (en) | 2012-12-28 | 2014-01-06 | Salts and crystal forms |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016145847A Division JP2016188243A (ja) | 2012-12-28 | 2016-07-25 | 塩および結晶形態 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016503752A JP2016503752A (ja) | 2016-02-08 |
| JP2016503752A5 true JP2016503752A5 (enExample) | 2017-08-03 |
| JP6210604B2 JP6210604B2 (ja) | 2017-10-11 |
Family
ID=51021464
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015527377A Active JP6210604B2 (ja) | 2012-12-28 | 2014-01-06 | 塩および結晶形態 |
| JP2016145847A Pending JP2016188243A (ja) | 2012-12-28 | 2016-07-25 | 塩および結晶形態 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016145847A Pending JP2016188243A (ja) | 2012-12-28 | 2016-07-25 | 塩および結晶形態 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9447066B2 (enExample) |
| EP (1) | EP2938607B1 (enExample) |
| JP (2) | JP6210604B2 (enExample) |
| KR (1) | KR102220999B1 (enExample) |
| CN (1) | CN104870431B (enExample) |
| ES (1) | ES2694422T3 (enExample) |
| RU (1) | RU2654855C2 (enExample) |
| TW (1) | TWI646091B (enExample) |
| WO (1) | WO2014104414A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI335218B (en) * | 2003-02-19 | 2011-01-01 | Panion & Bf Biotech Inc | Ferric organic compounds, uses thereof and methods of making same |
| EP2979695B1 (en) * | 2013-03-29 | 2018-08-01 | AskAt Inc. | Therapeutic agent for ocular disease |
| CN115813888A (zh) | 2016-12-20 | 2023-03-21 | 罗曼治疗系统股份公司 | 包含阿塞那平的透皮治疗系统 |
| EP3558276B1 (en) | 2016-12-20 | 2024-11-06 | LTS Lohmann Therapie-Systeme AG | Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene |
| CN108926528A (zh) * | 2017-05-25 | 2018-12-04 | 北京万全德众医药生物技术有限公司 | 含有氨磺必利树脂酸盐的口服液体组合物 |
| WO2019002204A1 (en) | 2017-06-26 | 2019-01-03 | Lts Lohmann Therapie-Systeme Ag | TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ASENAPINE AND SILICONE-TYPE ACRYLIC HYBRID POLYMER |
| US12329862B2 (en) | 2018-06-20 | 2025-06-17 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
| AU2019291060B2 (en) | 2018-06-20 | 2024-09-05 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
| DE102022134398B3 (de) | 2022-12-21 | 2024-05-23 | FAE Elektrotechnik GmbH & Co. KG | Portables Speichersystem für Kraftstoffe sowie Ringdruckspeicher und Gehäuse für das Speichersystem |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4394382A (en) * | 1980-06-17 | 1983-07-19 | Kowa Company, Ltd. | Dihydrobenzopyran compounds and pharmaceutical composition comprising said compounds |
| US4577534A (en) | 1985-04-01 | 1986-03-25 | Chrysler Corporation | Front suspension alignment tool |
| JPH10293205A (ja) | 1997-04-18 | 1998-11-04 | Minolta Co Ltd | 回折光学素子及び金型の製造方法 |
| US6034256A (en) * | 1997-04-21 | 2000-03-07 | G.D. Searle & Co. | Substituted benzopyran derivatives for the treatment of inflammation |
| US6077850A (en) | 1997-04-21 | 2000-06-20 | G.D. Searle & Co. | Substituted benzopyran analogs for the treatment of inflammation |
| US20040072889A1 (en) | 1997-04-21 | 2004-04-15 | Pharmacia Corporation | Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia |
| US20030225150A1 (en) | 1997-04-21 | 2003-12-04 | Pharmacia Corporation | Method of using a COX-2 inhibitor and a topoisomerase II inhibitor as a combination therapy in the treatment of neoplasia |
| US20030013739A1 (en) | 1998-12-23 | 2003-01-16 | Pharmacia Corporation | Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia |
| AU2592600A (en) | 1998-12-23 | 2000-07-31 | G.D. Searle & Co. | Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| US20030119895A1 (en) | 1998-12-23 | 2003-06-26 | Pharmacia Corporation | Methods using a combination of a 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia |
| US6858598B1 (en) | 1998-12-23 | 2005-02-22 | G. D. Searle & Co. | Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| US20040122011A1 (en) | 1998-12-23 | 2004-06-24 | Pharmacia Corporation | Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy |
| US20050037090A1 (en) | 1998-12-23 | 2005-02-17 | Mckearn John P. | Combination therapy including a cyclooxygenase-2 inhibitor and an antineoplastic agent |
| US20030203956A1 (en) | 1998-12-23 | 2003-10-30 | Masterrer Jaime L. | Method of using a cyclooxygenase-2 inhibitor and one or more ornithine decarboxylase inhibitors as a combination therapy in the treatment of neoplasia |
| US20040127470A1 (en) | 1998-12-23 | 2004-07-01 | Pharmacia Corporation | Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist |
| US20020103141A1 (en) | 1998-12-23 | 2002-08-01 | Mckearn John P. | Antiangiogenic combination therapy for the treatment of cancer |
| US20040053900A1 (en) | 1998-12-23 | 2004-03-18 | Pharmacia Corporation | Method of using a COX-2 inhibitor and an aromatase inhibitor as a combination therapy |
| US6649645B1 (en) | 1998-12-23 | 2003-11-18 | Pharmacia Corporation | Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia |
| US6833373B1 (en) | 1998-12-23 | 2004-12-21 | G.D. Searle & Co. | Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| US20030153801A1 (en) | 2001-05-29 | 2003-08-14 | Pharmacia Corporation | Compositions of cyclooxygenase-2 selective inhibitors and radiation for inhibition or prevention of cardiovascular disease |
| AR038957A1 (es) * | 2001-08-15 | 2005-02-02 | Pharmacia Corp | Terapia de combinacion para el tratamiento del cancer |
| MXPA04006572A (es) * | 2002-01-10 | 2005-11-04 | Upjohn Co | Terapia de combinacion antivirica. |
| MX2007000880A (es) * | 2004-07-23 | 2007-03-12 | Upjohn Co | Metodo enantioselectivo para separar derivados de acido 3-trifluorometil-2h-cromeno-3-carboxilico sustituido. |
| EP1844040A1 (en) * | 2005-01-21 | 2007-10-17 | Pfizer Limited | Crystalline forms of cis-5-fluoro-n-[4-(2-hydroxy-4-methylbenzamido)cyclohexyl]-2-(tetrahydrothiopyran-4-yloxy)nicotinamide |
| AR053046A1 (es) | 2005-04-07 | 2007-04-18 | Teijin Pharma Ltd | Cristal de derivado de aminonopirrolidina y metodo de produccion del mismo |
| BRPI0611170A2 (pt) | 2005-05-27 | 2010-08-17 | Panacea Biotec Ltd | composições injetáveis e processo para o preparo de tais composições |
| WO2008065502A1 (en) * | 2006-11-29 | 2008-06-05 | Pfizer Products Inc. | Pharmaceutical compositions based on a) nanoparticles comprising enteric polymers and b) casein |
-
2013
- 2013-12-30 TW TW102149127A patent/TWI646091B/zh active
-
2014
- 2014-01-06 WO PCT/JP2014/000010 patent/WO2014104414A1/en not_active Ceased
- 2014-01-06 US US14/655,175 patent/US9447066B2/en active Active
- 2014-01-06 CN CN201480003563.4A patent/CN104870431B/zh active Active
- 2014-01-06 RU RU2015130602A patent/RU2654855C2/ru active
- 2014-01-06 ES ES14733062.5T patent/ES2694422T3/es active Active
- 2014-01-06 KR KR1020157019802A patent/KR102220999B1/ko active Active
- 2014-01-06 EP EP14733062.5A patent/EP2938607B1/en active Active
- 2014-01-06 JP JP2015527377A patent/JP6210604B2/ja active Active
-
2016
- 2016-07-25 JP JP2016145847A patent/JP2016188243A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016503752A5 (enExample) | ||
| RU2015130602A (ru) | Соли и кристаллические формы | |
| JP3665053B2 (ja) | 純結晶形態の５−クロロ−３−（４−メタンスルホニルフェニル）−６’−メチル−［２，３’］ビピリジニルおよび合成方法 | |
| KR102279371B1 (ko) | 상이한 결정형의 5-브로모-2-(α-하이드록시펜틸)벤조산 나트륨 염 및 그의 제조 방법 | |
| JP2018527363A (ja) | リナグリプチン結晶形及びこの製造方法 | |
| TWI745289B (zh) | 一種週期素依賴性蛋白激酶抑制劑的結晶形式及其製備方法 | |
| CN106748873B (zh) | 一种维生素b5机械研磨固相制备方法 | |
| CN101525321A (zh) | 多烯紫杉醇倍半水结晶体及其制备方法 | |
| CN107033094A (zh) | 一种药物共晶的晶型及其制备方法和组合物 | |
| JP6392320B2 (ja) | 結晶性３’，５’−サイクリックジグアニル酸 | |
| CN111315748B (zh) | 3-(5-氟苯并呋喃-3-基)-4-(5-甲基-5H-[1,3]间二氧杂环戊烯并[4,5-f]吲哚-7-基)吡咯-2,5-二酮晶体 | |
| JP7014719B2 (ja) | 置換アミノピラン誘導体の結晶形 | |
| CN111630045A (zh) | 喹啉衍生物的结晶 | |
| AU2015206758A1 (en) | Solid forms of tenofovir | |
| WO2019037591A1 (zh) | 盐酸美法仑晶型及其制备方法与应用 | |
| EP3440064B1 (en) | Process for preparing oxathiazin-like compounds | |
| CN105622408A (zh) | 双(2-乙酰氧基苯甲酸)钙脲化合物的制备方法 | |
| TW201643142A (zh) | 製備白克列之方法 | |
| JP2018509466A (ja) | Ａｈｕ３７７の結晶形、その製造方法及び用途 | |
| JP6711709B2 (ja) | エゼチミブの製造方法 | |
| NZ630287A (en) | Crystalline bortezomib process | |
| CN104788330B (zh) | 一种手性双l‑亮氨酸盐酸盐的制备及合成方法 | |
| CN109251218A (zh) | 一种取代的硼酸酯化合物的制备方法及其晶型 | |
| US11014890B2 (en) | Forms of (R)-N-(4-chlorophenyl)-2-(cis-4-(6-fluoroquinolin-4- yl)cyclohexyl)propanamide | |
| TW201625593A (zh) | （２ｓ，４ｒ）－４－［４－（１－甲基－１ｈ－吡唑－４－基）－２－三氟甲基－苯磺醯基］－１－（１－三氟甲基－環丙烷羰基）－吡咯啶－２－羧酸（１－氰基－環丙基）－醯胺之固體形式 |